“Generics” and “biosimilars” are a distinct category of drugs that undergo different development pathways, are subjected to different regulatory requirements and market dynamics. Generic products are copies of small molecule products and are typically developed after the original, or reference product, small-molecule patent expires. Generic products must demonstrate bioequivalence to the reference product and are manufactured using standardized chemical processes. The approval of generics requires evidence that demonstrates bioequivalence, without the need for extensive clinical trials.
Biosimilars, on the other hand, mimic complex biologics and are highly similar to biologic products that are already approved. These products tend to be large, complex, and derived from living organisms. Even though they are not identical to the original reference biologic product (due to inherent variability in the production of the biologic), they must demonstrate “no clinically meaningful differences” in the safety, purity, or potency. Usually, biosimilar requires advanced biotechnological processes and extensive comparative analysis. In order to obtain approval, rigorous analytical studies, animal testing, and clinical trials are required to confirm similarity.
Market Impact of Biosimilars and Generics
Generic products have played an important role in providing cost-effective treatment options. Healthcare systems and patients as subject to substantial cost savings due to the availability of generic products. Typically, generic products are mainly prescribed by GPs and dispensed through pharmacies. According to a review article by Katelijne van de Voorsen, generic products tend to be anywhere between 50 and 80% cheaper than originator products as a result of lower development costs.
The introduction of biosimilars has had a significant impact on the biologics sector. Not only have they fostered competition in previously monopolized therapeutic areas, but they have also helped reduce the cost for life-saving treatments for complex conditions (i.e., cancer, diabetes, rheumatoid arthritis). Biosimilars are typically prescribed by specialists and used in hospitals before being made available to patients. The price reduction for biosimilars is relatively smaller compared to generics (between 20 and 35%) due to higher costs associated with development and production.
Challenges in Market Adoption
Generics are more easily accepted by physicians however, biosimilars face hurdles such as misinformation about efficacy and safety, varying global regulations, speed & extent of approvals, high manufacturing and development costs, and stringent control requirements. In order to increase adoption of biosimilars, changes pertaining to patent regulations, competitive tenders, and policy adjustments should be considered.
Conclusion
Even though both generics and biosimilars provide cost-effective treatment alternatives compared to their originators, their unique characteristics and development pathways tend to define their role in and impact on the pharmaceutical landscape. This is also includes their regulatory environment. As the healthcare industry continues to evolve, biosimilar adoption will be driven by how well and efficiently the market challenges are addressed. By balancing affordability with innovation, generics and biosimilars can shape a much more sustainable and accessible healthcare system across the globe.
Are you looking for expert support to enhance market access of generic and biosimilar products? Need guidance in navigating the regulatory framework for global markets? Reach out to us today!
Read more from us here: Project Orbis: Transforming Global Cancer Treatment Access